HIV-associated adipose redistribution syndrome (HARS): Definition, epidemiology and clinical impact

AIDS Research and Therapy

Volumn 4, Issue , 2007, Pages

  Lichtenstein, Kenneth ^a   Balasubramanyam, Ashok ^b   Sekhar, Rajagopal ^b   Freedland, Eric ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c EMD SERONO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADIPOSE TISSUE; BODY FAT DISTRIBUTION; CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; FATTY LIVER; HEALTH HAZARD; HEART INFARCTION; HIV ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPOATROPHY; LIPOHYPERTROPHY; PATIENT ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; WAIST HIP RATIO;

EID: 34748822377     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-4-16     Document Type: Review

References (112)

1. Garcia-Viejo MA Ruiz M Martinez E Strategies for treating HIV-related lipodystrophy Expert Opin Investig Drugs 2001, 10:1443-1456 10.1517/ 13543784.10.8.1443 11772261
2. Powderly WG Long-term exposure to lifelong therapies J Acquir Immune Defic Syndr 2002, 29(Suppl 1):S28-40 11832699
3. Carr A Samaras K Burton S Law M Freund J Chisholm DJ Cooper DA A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors AIDS 1998, 12:F51-58 10.1097/00002030-199807000-00003 9619798
4. Engelson ES Kotler DP Tan Y Agin D Wang J Pierson RN Jr Heymsfield SB Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging Am J Clin Nutr 1999, 69:1162-1169 10357734
5. Herry I Bernand L de Truchis P Perronne C Hypertrophy of the breasts in a patient treated with indinavir Clin Infect Dis 1997, 25:937-938 9356823
6. Lo JC Mulligan K Tai VW Algren H Schambelan M "Buffalo hump" in men with HIV-1 infection Lancet 1998, 351:867-870 10.1016/ S0140-6736(97)11443-X 9525364
7. Massip P Marchou B Bonnet E Cuzin L Montastruc JL Lipodystrophia with protease inhibitors in HIV patients Therapie 1997, 52:615 9734120
8. Miller KD Jones E Yanovski JA Shankar R Feuerstein I Falloon J Visceral abdominal-fat accumulation associated with use of indinavir Lancet 1998, 351:871-875 10.1016/S0140-6736(97)11518-5 9525365
9. Bacchetti P Gripshover B Grunfeld C Heymsfield S McCreath H Osmond D Saag M Scherzer R Shlipak M Tien P Fat distribution in men with HIV infection J Acquir Immune Defic Syndr 2005, 40:121-131 10.1097/ 01.qai.0000182230.47819.aa 16186728
10. Safrin S Grunfeld C Fat distribution and metabolic changes in patients with HIV infection AIDS 1999, 13:2493-2505 10.1097/ 00002030-199912240-00002 10630518
11. Sattler F Body habitus changes related to lipodystrophy Clin Infect Dis 2003, 36:S84-90 10.1086/367563 12652376
12. Tien PC Grunfeld C What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection Curr Opin Infect Dis 2004, 17:27-32 10.1097/00001432-200402000-00005 15090886
13. Freedland ES Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: Implications for controlling dietary carbohydrates: A review Nutr Metab (Lond) 2004, 1:12 535537 15530168 10.1186/1743-7075-1-12
14. Vigano A Mora S Manzoni P Schneider L Beretta S Molinaro M di Natale B Brambilla P Effects of recombinant growth hormone on visceral fat accumulation: Pilot study in human immunodeficiency virus-infected adolescents J Clin Endocrinol Metab 2005, 90:4075-4080 10.1210/ jc.2004-2431 15840750
15. Yin MT Glesby MJ Recombinant human growth hormone therapy in HIV-associated wasting and visceral adiposity Expert Rev Anti Infect Ther 2005, 3:727-738 10.1586/14787210.3.5.727 16207164
16. Roth VR Kravcik S Angel JB Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors Clin Infect Dis 1998, 27:65-67 9675453
17. Torres RA Unger KW Cadman JA Kassous JY Recombinant human growth hormone improves truncal adiposity and 'buffalo humps' in HIV-positive patients on HAART AIDS 1999, 13:2479-2481 10.1097/00002030-199912030-00023 10597793
18. Zolopa A Benson C Bacchetti P Tien PC Grunfeld C Buffalo hump in men with HIV Infection: Larger, but not more common 10th Conference on Retroviruses and Opportunistic Infections: Incidence, Prevalence, and Impact of Body Composition Abnormalities; Boston, MA 2003 2003
19. Lichtenstein KA Delaney KM Armon C Ward DJ Moorman AC Wood KC Holmberg SD Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients J Acquir Immune Defic Syndr 2003, 32:48-56 12514413
20. Martin A Mallon PW Therapeutic approaches to combating lipoatrophy: Do they work? J Antimicrob Chemother 2005, 55:612-615 10.1093/jac/dki062 15761072
21. Parruti G Toro GM Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: Case report BMC Infect Dis 2005, 5:80 1261268 16202141 10.1186/1471-2334-5-80
22. Fliers E Sauerwein HP Romijn JA Reiss P van der Valk M Kalsbeek A Kreier F Buijs RM HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy Lancet 2003, 362:1758-1760 10.1016/ S0140-6736(03)14858-1 14643128
23. Grunfeld C Thompson M Brown SJ Richmond G Lee D Muurahainen N Kotler DP Recombinant Human Growth Hormone to Treat HIV-Associated Adipose Redistribution Syndrome: 12-Week Induction and 24-Week Maintenance Therapy J Acquir Immune Defic Syndr 2007, 45:286-297 17592343
24. Kotler DP Muurahainen N Grunfeld C Wanke C Thompson M Saag M Bock D Simons G Gertner JM Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients J Acquir Immune Defic Syndr 2004, 35:239-252 10.1097/ 00126334-200403010-00004 15076238
25. Kotler DP Muurahainen N Grunfeld C Wanke C Thompson M Saag M Bock D Simons G Gertner JM Effects of growth hormone on visceral adipose tissue and dyslipidemia in HIV, an erratum J Acquir Immune Defic Syndr 2006, 43:378-380 10.1097/01.qai.0000243108.26136.66 17079997
26. Pond CM Long-term changes in adipose tissue in human disease Proc Nutr Soc 2001, 60:365-374 11681811
27. van Gurp PJ Tack CJ van der Valk M Reiss P Lenders JW Sweep FC Sauerwein HP Sympathetic nervous system function in HIV-associated adipose redistribution syndrome AIDS 2006, 20:773-775 10.1097/ 01.aids.0000216379.91936.84 16514309
28. Dolan SE Hadigan C Killilea KM Sullivan MP Hemphill L Lees RS Schoenfeld D Grinspoon S Increased cardiovascular disease risk indices in HIV-infected women J Acquir Immune Defic Syndr 2005, 39:44-54 10.1097/ 01.qai.0000159323.59250.83 15851913
29. Hadigan C Meigs JB Corcoran C Rietschel P Piecuch S Basgoz N Davis B Sax P Stanley T Wilson PW Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy Clin Infect Dis 2001, 32:130-139 10.1086/317541 11118392
30. Turner R Testa MA Su M Richmond G Muurahainen N Kotler DP Thompson M The impact of HIV-associated adipose redistribution syndrome (HARS) on health-related quality of life Antiviral Therapy 2006, 11:L25
31. Gripshover B Tien PC Saag M Osmond D Bacchetti P Grunfeld C Lipoatrophy is the Dominant Feature of the Lipodystrophy Syndrome in HIV-infected Men Conf Retrovir Oppor Infect 2003.
32. Carr A HIV lipodystrophy: Risk factors, pathogenesis, diagnosis and management AIDS 2003, 17(Suppl 1):S141-148 12870540
33. Engelson ES HIV lipodystrophy diagnosis and management. Body composition and metabolic alterations: Diagnosis and management AIDS Read 2003, 13:S10-14 12762288
34. Mondy K Tong S Kessels L Powderly W Overton E Metabolic Syndrome in HIV within a Representative US patient Population 13th Conference on Retroviruses and Opportunistic Infections: Metabolic Syndrome and Other Abnormalities of Fat, Lipid, Glucose and Bone Metabolism. Denver, CO 2006.
35. Kotler D Engelson E Heymsfield S Chang P Muurahainen N Gertner J Anthropometric Criteria define visceral fat excess in patients with HIV-associated adipose redistribution syndrome (HARS), a subset of HIV lipodystrophy (abstract) 9th Conference on Retroviruses and Opportunistic Infections: Incidence, Prevalence, and Pathogenic Correlates of Insulin Resistance and Lipodystrophy Syndrome, Seattle, WA 2002.
36. Kotler DP Muurahainen N Chang P Engelson ES Wang J Heymsfield SB Gertner JM Anthropometric equations select HIV+ men and women with distinctly abnormal fat accumulation and distribution Int Conf AIDS; 2002 Jul 7-12;14:(Abstract no. WePeB5997) 2002
37. Wanke C Editorial comment: A case definition for HIV lipodystrophy - a work in progress AIDS Read 2003, 13:492-493 14596226
38. Benavides S Nahata MC Pharmacologic therapy for HIV-associated lipodystrophy Ann Pharmacother 2004, 38:448-457 10.1345/aph.1D081 14755064
39. Belloso WH Quiros RE Ivalo SA Perman MI Galich AM Stern LD Barcan LA Agreement analysis of variables involved in lipodystrophy syndrome definition in HIV-infected patients J Acquir Immune Defic Syndr 2003, 32:104-111 12514421
40. Carr A Emery S Law M Puls R Lundgren JD Powderly WG An objective case definition of lipodystrophy in HIV-infected adults: A case-control study Lancet 2003, 361:726-735 10.1016/S0140-6736(03)12656-6 12620736
41. Carr A Law M An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score J Acquir Immune Defic Syndr 2003, 33:571-576 HIV Lipodystrophy Case Definition Study Group 10.1097/ 00126334-200308150-00004 12902800
42. Thiebaut R Daucourt V Mercie P Ekouevi DK Malvy D Morlat P Dupon M Neau D Farbos S Marimoutou C Dabis F Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine Clin Infect Dis 2000, 31:1482-1487 10.1086/317477 11096016
43. Miller JE Emery S French M Baker D Cooper DA The Australian prevalence survey of lipodystrophy 7th Conference on Retroviruses and Opportunistic Infections. San Francisco; CA; 2000 2000
44. Ward DJ Delaney KM Moorman AC Lichtenstein K Palella F Young B Wood KC Holmberg SD Description of lipodystrophy in the HIV outpatient study (HOPS) Antiviral Therapy 1999, 4(Suppl 2):. 11403019
45. Saint-Marc T Partisani M Poizot-Martin I Rouviere O Bruno F Avellaneda R Lang JM Gastaut JA Touraine JL Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study AIDS 2000, 14:37-49 10.1097/00002030-200001070-00005 10714566
46. Bergersen BM Sandvik L Bruun JN Body composition changes in 308 Norwegian HIV-positive patients Scand J Infect Dis 2004, 36:186-191 10.1080/00365540410019273 15119363
47. Bernasconi E Boubaker K Junghans C Flepp M Furrer HJ Haensel A Hirschel B Boggian K Chave JP Opravil M Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study J Acquir Immune Defic Syndr 2002, 31:50-55 12352150
48. Miller J Brown D Amin J Kent-Hughes J Law M Kaldor J Cooper DA Carr A A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia AIDS 2002, 16:2195-2200 10.1097/00002030-200211080-00012 12409741
49. Miller J Carr A Emery S Law M Mallal S Baker D Smith D Kaldor J Cooper DA HIV lipodystrophy: Prevalence, severity and correlates of risk in Australia HIV Med 2003, 4:293-301 10.1046/j.1468-1293.2003.00159.x 12859330
50. Lichtenstein K Wanke C Henry K Thompson M Muurahainen N Kotler DP Estimated Prevalence of HIV-associated adipose redistribution syndrome (HARS) - abnormal abdominal fat accumulation - in HIV-infected patients Antiviral Therapy 2004, 9:L33
51. Paparizos VA Kyriakis KP Polydorou-Pfandl D Hadjivassiliou M Stavrianeas NG Epidemiologic characteristics of Koebner's phenomenon in AIDS-related Kaposi's sarcoma J Acquir Immune Defic Syndr 2000, 25:283-284 10.1097/ 00042560-200011010-00013 11115960
52. Rozenbaum W Gharakhanian S Salhi Y Adda N Nguyen T Vigouroux C Capeau J Clinical and laboratory characteristics of lipodystrophy in a French cohort of HIV-infected patients treated with protease inhibitors Antivir Ther 1999, 4(Suppl 2):L34
53. Saves M Raffi F Capeau J Rozenbaum W Ragnaud JM Perronne C Basdevant A Leport C Chene G Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy Clin Infect Dis 2002, 34:1396-1405 10.1086/339866 11981737
54. Kotler D Update from the 7th international workshop on adverse drug reactions and lipodystrophy in HIV The PRN Notebook 2006, 11:16-21
55. Mulligan K Parker R Komarow L Tebas P Grinspoon S Robbins G Dube M ACTG 5005S and 384 Study Teams Mixed patterns of changes in central and peripheral fat following initiation of ART 12th Conference on Retroviruses and Opportunistic Infections February; Boston, MA; 2005 2005
56. Kuk JL Katzmarzyk PT Nichaman MZ Church TS Blair SN Ross R Visceral Fat Is an Independent Predictor of All-cause Mortality in Men Obesity (Silver Spring) Research 2006, 14:336-341
57. Grunfeld C Tien P Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome Clin Infect Dis 2003, 37(Suppl 2):S43-46 10.1086/375886 12942373
58. NCEP Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 2001, 285:2486-2497 10.1001/jama.285.19.2486 11368702
59. Wohl DA Body shape, lipid, and cardiovascular complications of HIV therapy Curr HIV/AIDS Rep 2005, 2:74-82 10.1007/s11904-005-0022-6 16091252
60. Lebovitz HE Banerji MA Point: Visceral adiposity is causally related to insulin resistance Diabetes Care 2005, 28:2322-2325 10.2337/ diacare.28.9.2322 16123512
61. Goodpaster BH Kelley DE Wing RR Meier A Thaete FL Effects of weight loss on regional fat distribution and insulin sensitivity in obesity Diabetes 1999, 48:839-847 10.2337/diabetes.48.4.839 10102702
62. Calza L Manfredi R Chiodo F Insulin resistance and diabetes mellitus in HIV infected patients receiving antiretroviral therapy Metabolic Syndrome and Related Disorders 2004, 2:241-250 10.1089/met.2004.2.241
63. Balasubramanyam A Sekhar RV Jahoor F Jones PH Pownall HJ Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of 'systemic steatosis' Curr Opin Lipidol 2004, 15:59-67 10.1097/ 00041433-200402000-00011 15166810
64. Hadigan C Kamin D Liebau J Mazza S Barrow S Torriani M Rubin R Weise S Fischman A Grinspoon S Depot-specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophy Am J Physiol Endocrinol Metab 2006, 290:E289-298 10.1152/ajpendo.00273.2005 16131513
65. Mallon PW Wand H Law M Miller J Cooper DA Carr A Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia J Acquir Immune Defic Syndr 2005, 38:156-162 HIV Lipodystrophy Case Definition Study; Australian Lipodystrophy Prevalence Survey Investigators. 10.1097/01.qai.0000147527.64863.1a 15671800
66. Shikuma CM Day LJ Gerschenson M Insulin resistance in the HIV-infected population: The potential role of mitochondrial dysfunction Curr Drug Targets Infect Disord 2005, 5:255-262 10.2174/1568005054880163 16181144
67. Triant VA Lee H Hadigan C Grinspoon SK Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors Among Patients with HIV Disease J Clin Endocrinol Metab 2007, 92:2506-2512 17456578 10.1210/ jc.2006-2190
68. Tanwani LK Mokshagundam SL Lipodystrophy, insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease in human immunodeficiency virus infection South Med J 2003, 96:180-188 quiz 189. 10.1097/01.SMJ.0000051731.69719.2E 12630645
69. Henry K Melroe H Huebsch J Hermundson J Levine C Swensen L Daley J Severe premature coronary artery disease with protease inhibitors Lancet 1998, 351:1328 10.1016/S0140-6736(05)79053-X 9643798
70. Friis-Moller N Reiss P Sabin CA Weber R Monforte A El-Sadr W Thiebaut R De Wit S Kirk O Fontas E Class of antiretroviral drugs and the risk of myocardial infarction N Engl J Med 2007, 356:1723-1735 10.1056/ NEJMoa062744 17460226
71. Yusuf S Hawken S Ounpuu S Bautista L Franzosi MG Commerford P Lang CC Rumboldt Z Onen CL Lisheng L Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: A case-control study Lancet 2005, 366:1640-1649 10.1016/S0140-6736(05)67663-5 16271645
72. Meininger G Hadigan C Rietschel P Grinspoon S Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men Am J Clin Nutr 2002, 76:460-465 12145023
73. Hadigan C Meigs JB Wilson PW D'Agostino RB Davis B Basgoz N Sax PE Grinspoon S Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution Clin Infect Dis 2003, 36:909-916 10.1086/368185 12652392
74. Williams P Wu J Cohn S Koletar S McCutchan J Murphy R Currier J Risk of Cardiovascular Disease in HIV-infected adults with immune reconstitution 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2005 2005
75. Samaras K Wand H Law M Emery S Cooper D Carr A Prevalence of Metabolic Syndrome in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy Using International Diabetes Foundation and Adult Treatment Panel III Criteria: Associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive peptide, and hypoadiponectinemia Diabetes Care 2007, 30:113-119 10.2337/dc06-1075 17192343
76. Samaras K Wand H Law M Metabolic syndrome in HIV-infected patients using IDF and ATP-3 criteria, prevalence, discordance, and clinical utility 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Francisco, CA; 2006 2006
77. Despres JP Lemieux I Abdominal obesity and metabolic syndrome Nature 2006, 444:881-887 10.1038/nature05488 17167477
78. Ristig M Drechsler H Powderly WG Hepatic steatosis and HIV infection AIDS Patient Care STDS 2005, 19:356-365 10.1089/apc.2005.19.356 15989431
79. Kelley DE McKolanis TM Hegazi RA Kuller LH Kalhan SC Fatty liver in type 2 diabetes mellitus: Relation to regional adiposity, fatty acids, and insulin resistance Am J Physiol Endocrinol Metab 2003, 285:E906-916 12959938
80. Nguyen-Duy TB Nichaman MZ Church TS Blair SN Ross R Visceral fat and liver fat are independent predictors of metabolic risk factors in men Am J Physiol Endocrinol Metab 2003, 284:E1065-1071 12554597
81. Reeds DN Yarasheski KE Fontana L Cade WT Laciny E DeMoss A Patterson BW Powderly WG Klein S Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia Am J Physiol Endocrinol Metab 2006, 290:E47-E53 10.1152/ajpendo.00236.2005 16118251
82. Meininger G Hadigan C Laposata M Brown J Rabe J Louca J Aliabadi N Grinspoon S Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution Metabolism 2002, 51:260-266 10.1053/meta.2002.29999 11833059
83. Feve B Adipogenesis: Cellular and molecular aspects Best Pract Res Clin Endocrinol Metab 2005, 19:483-499 10.1016/j.beem.2005.07.007 16311213
84. Sutinen J Hakkinen AM Westerbacka J Seppala-Lindroos A Vehkavaara S Halavaara J Jarvinen A Ristola M Yki-Jarvinen H Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy AIDS 2002, 16:2183-2193 10.1097/ 00002030-200211080-00011 12409740
85. Luzi L Perseghin G Tambussi G Meneghini E Scifo P Pagliato E Del Maschio A Testolin G Lazzarin A Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy Am J Physiol Endocrinol Metab 2003, 284:E274-280 12388139
86. Martinez E Garcia-Viejo MA Blanch L Gatell JM Lipodystrophy syndrome in patients with HIV infection: Quality of life issues Drug Saf 2001, 24:157-166 10.2165/00002018-200124030-00001 11347720
87. Persson A Facing HIV: Body shape change and the (in)visibility of illness Med Anthropol 2005, 24:237-264 10.1080/01459740500182683 16081335
88. Duran S Saves M Spire B Cailleton V Sobel A Carrieri P Salmon D Moatti JP Leport C Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy AIDS 2001, 15:2441-2444 10.1097/00002030-200112070-00012 11740195
89. Hawkins T Appearance-related side effects of HIV-1 treatment AIDS Patient Care STDS 2006, 20:6-18 10.1089/apc.2006.20.6 16426151
90. Burgoyne R Collins E Wagner C Abbey S Halman M Nur M Walmsley S The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults Qual Life Res 2005, 14:981-990 10.1007/s11136-004-2580-2 16041895
91. Engelson ES Interventions for visceral adiposity associated with human immunodeficiency virus: Application of a method for assessing efficacy Clin Infect Dis 2003, 37(Suppl 2):S96-100 10.1086/375880 12942381
92. Grinspoon S Gelato M Editorial: The rational use of growth hormone in HIV-infected patients J Clin Endocrinol Metab 2001, 86:3478-3479 10.1210/ jc.86.8.3478 11502766
93. Reynolds NR Neidig JL Wu AW Gifford AL Holmes WC Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution AIDS Care 2006, 18:663-673 10.1080/09540120500287051 16971273
94. Gold DR Annino DJ Jr HIV-associated cervicodorsal lipodystrophy: etiology and management Laryngoscope 2005, 115:791-795 10.1097/ 01.MLG.0000161838.22766.88 15867641
95. Guaraldi G Orlando G Squillace N Roverato A De Fazio D Vandelli M Nardini G Beghetto B De Paola M Esposito R Palella F Prevalence of and Risk Factors for Pubic Lipoma Development in HIV-Infected Persons J Acquir Immune Defic Syndr 2007, 45:72-76 10.1097/QAI.0b013e31804a85b0 17460472
96. Chen D Misra A Garg A Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients J Clin Endocrinol Metab 2002, 87:4845-4856 10.1210/jc.2002-020794 12414837
97. Garg A Lipodystrophies Am J Med 2000, 108:143-152 10.1016/ S0002-9343(99)00414-3 11126308
98. Garg A Acquired and inherited lipodystrophies N Engl J Med 2004, 350:1220-1234 10.1056/NEJMra025261 15028826
99. Garg A Peshock RM Fleckenstein JL Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety) J Clin Endocrinol Metab 1999, 84:170-174 10.1210/jc.84.1.170 9920078
100. Kosmiski L Kuritzkes D Hamilton J Sharp T Lichtenstien K Hill J Eckel R Fat distribution is altered in HIV-infected men without clinical evidence of the HIV lipodystrophy syndrome HIV Med 2003, 4:235-240 10.1046/j.1468-1293.2003.00151.x 12859322
101. Brown T Wang Z Chu H Palella F Kingsley L Witt MD Dobs AS Longitudinal Anthropometric Changes in HIV-Infected and HIV-Uninfected Men J Acquir Immune Defic Syndr 2006, 43:356-362 10.1097/01.qai.0000243052.73321.8e 16980910
102. Palella FJ Jr Chmiel JS Riddler SA Calhoun B Dobs A Visscher B Kingsley L A novel pattern of lipoaccumulation in HIV-infected men JAMA 2006, 296:766-768 10.1001/jama.296.7.766 16905782
103. Schwenk A Methods of assessing body shape and composition in HIV-associated lipodystrophy Curr Opin Infect Dis 2002, 15:9-16 11964900
104. Schwenk A Breuer P Kremer G Ward L Clinical assessment of HIV-associated lipodystrophy syndrome: Bioelectrical impedance analysis, anthropometry and clinical scores Clin Nutr 2001, 20:243-249 10.1054/clnu.2001.0395 11407871
105. Falutz J Allas S Kotler D Thompson M Koutkia P Albu J Trottier B Routy JP Cote P Abribat T Grinspoon S A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation AIDS 2005, 19:1279-1287 10.1097/ 01.aids.0000180099.35146.30 16052083
106. Molarius A Seidell JC Selection of anthropometric indicators for classification of abdominal fatness - a critical review Int J Obes Relat Metab Disord 1998, 22:719-727 10.1038/sj.ijo.0800660 9725630
107. Chang P Kotler DP Engelson ES Gertner JG Kenley S Muurahainen N Anthropometric equations distinguish between HIV+ subjects affected and unaffected with HIV-associated adipose redistribution syndrome (HARS) 40th ICAAC. Toronto, Canada 2002.
108. Fichtenbaum CJ Hadigan CM Kotler DP Pierone G Jr Sax PE Steinhart CR Tebas P Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS Care IAPAC Mon 2005, 11:38-46 15971353
109. Larsson B Svardsudd K Welin L Wilhelmsen L Bjorntorp P Tibblin G Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913 Br Med J (Clin Res Ed) 1984, 288:1401-1404 1441047 6426576
110. Schambelan M Benson CA Carr A Currier JS Dube MP Gerber JG Grinspoon SK Grunfeld C Kotler DP Mulligan K Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel J Acquir Immune Defic Syndr 2002, 31:257-275 12439201
111. Cavalcanti RB Cheung AM Raboud J Walmsley S Reproducibility of DXA estimations of body fat in HIV lipodystrophy: Implications for clinical research J Clin Densitom 2005, 8:293-297 10.1385/JCD:8:3:293 16055959
112. Wang J Standardization of waist circumference reference data Am J Clin Nutr 2006, 83:3-4 16400041